Amphastar Pharmaceuticals Gross Margin 2012-2024 | AMPH

Current and historical gross margin for Amphastar Pharmaceuticals (AMPH) over the last 10 years. The current gross profit margin for Amphastar Pharmaceuticals as of September 30, 2024 is %.
Amphastar Pharmaceuticals Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-09-30 $0.72B $0.38B 52.97%
2024-06-30 $0.71B $0.39B 54.56%
2024-03-31 $0.68B $0.37B 54.21%
2023-12-31 $0.65B $0.35B 54.42%
2023-09-30 $0.60B $0.33B 54.15%
2023-06-30 $0.54B $0.28B 51.20%
2023-03-31 $0.52B $0.27B 51.54%
2022-12-31 $0.50B $0.25B 50.00%
2022-09-30 $0.48B $0.23B 48.35%
2022-06-30 $0.48B $0.23B 47.48%
2022-03-31 $0.46B $0.21B 46.15%
2021-12-31 $0.44B $0.20B 45.43%
2021-09-30 $0.41B $0.18B 43.58%
2021-06-30 $0.38B $0.17B 43.23%
2021-03-31 $0.37B $0.15B 41.30%
2020-12-31 $0.35B $0.14B 41.14%
2020-09-30 $0.34B $0.14B 41.54%
2020-06-30 $0.33B $0.14B 41.32%
2020-03-31 $0.33B $0.14B 41.90%
2019-12-31 $0.32B $0.13B 40.68%
2019-09-30 $0.33B $0.13B 40.43%
2019-06-30 $0.33B $0.13B 39.08%
2019-03-31 $0.32B $0.12B 38.17%
2018-12-31 $0.30B $0.11B 36.27%
2018-09-30 $0.27B $0.09B 34.72%
2018-06-30 $0.25B $0.08B 34.01%
2018-03-31 $0.24B $0.09B 35.27%
2017-12-31 $0.24B $0.09B 37.92%
2017-09-30 $0.24B $0.09B 37.30%
2017-06-30 $0.25B $0.10B 39.20%
2017-03-31 $0.25B $0.10B 40.71%
2016-12-31 $0.26B $0.11B 41.18%
2016-09-30 $0.27B $0.12B 44.03%
2016-06-30 $0.27B $0.11B 40.30%
2016-03-31 $0.25B $0.09B 35.04%
2015-12-31 $0.25B $0.08B 30.56%
2015-09-30 $0.23B $0.06B 24.24%
2015-06-30 $0.23B $0.05B 22.03%
2015-03-31 $0.22B $0.05B 23.42%
2014-12-31 $0.21B $0.05B 24.64%
2014-09-30 $0.21B $0.06B 28.57%
2014-06-30 $0.21B $0.07B 32.54%
2014-03-31 $0.22B $0.08B 35.87%
2013-12-31 $0.23B $0.09B 37.83%
2013-09-30 $0.23B $0.12B 52.42%
2013-06-30 $0.23B $0.16B 69.33%
2013-03-31 $0.21B $0.18B 84.36%
2012-12-31 $0.20B $0.20B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.097B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00